Literature DB >> 6452910

Decreased receptor-binding sites for kainic acid in brains of patients with Huntington's disease.

E D London, H I Yamamura, E D Bird, J T Coyle.   

Abstract

The specific binding of (3H)kainic acid (KA) to high- and low-affinity receptor sites was assayed in postmortem samples from the brains of patients affected with Huntington's disease (HD) and age-matched controls. Treatment of rat brain with conditions that closely mimic the temperature gradient occurring in postmortem human brain only slightly but not significantly decreased receptor binding by 12 hr after death. In HD brains, total specific binding of (3H)KA was reduced in the caudate nucleus by 51%, putamen by 77%, and frontal cortex by 47%. Specific binding to the high-affinity site was virtually undetectable in the caudate nucleus and was reduced by 90% in the putamen from HD brains. No significant alterations in specific binding of (3H)KA were noted in the insular or temporal cortex, hippocampus, or cerebellum. Thus, losses of KA receptor binding were mainly localized to those regions of the HD brain that are most severely affected by neuronal degeneration, and the high-affinity receptor site appeared more affected.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6452910

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

Authors:  S W Davies; M Turmaine; B A Cozens; A S Raza; A Mahal; L Mangiarini; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

Authors:  J H Cha; A S Frey; S A Alsdorf; J A Kerner; C M Kosinski; L Mangiarini; J B Penney; S W Davies; G P Bates; A B Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

4.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene.

Authors:  J H Cha; C M Kosinski; J A Kerner; S A Alsdorf; L Mangiarini; S W Davies; J B Penney; G P Bates; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

6.  Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection.

Authors:  E Spargo; I P Everall; P L Lantos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.